| Drug General Information |
| Drug ID |
D0GX7G
|
| Former ID |
DNC008738
|
| Drug Name |
N5-(1-iminobutyl)-L-ornithine
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C9H19N3O2
|
| Canonical SMILES |
CCCC(=NCCCC(C(=O)O)N)N
|
| InChI |
1S/C9H19N3O2/c1-2-4-8(11)12-6-3-5-7(10)9(13)14/h7H,2-6,10H2,1H3,(H2,11,12)(H,13,14)/t7-/m0/s1
|
| InChIKey |
KRILJVOCVSUPMA-ZETCQYMHSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Nitric-oxide synthase, endothelial |
Target Info |
Inhibitor |
[1]
|
|---|
| Nitric-oxide synthase, brain |
Target Info |
Inhibitor |
[1]
|
| Nitric oxide synthase, inducible |
Target Info |
Inhibitor |
[1]
|
|
BioCyc Pathway
|
Citrulline-nitric oxide cyclePWY-4983:Citrulline-nitric oxide cyclePWY-4983:Citrulline-nitric oxide cycle
|
|
KEGG Pathway
|
Arginine and proline metabolism
|
|
Metabolic pathways
|
|
Calcium signaling pathway
|
|
cGMP-PKG signaling pathway
|
|
HIF-1 signaling pathway
|
|
Sphingolipid signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
VEGF signaling pathway
|
|
Platelet activation
|
|
Estrogen signaling pathway
|
|
Oxytocin signaling pathwayhsa00330:Arginine and proline metabolism
|
|
Phagosome
|
|
Circadian entrainment
|
|
Long-term depression
|
|
Salivary secretion
|
|
Alzheimer's disease
|
|
Amyotrophic lateral sclerosis (ALS)hsa00220:Arginine biosynthesis
|
|
Peroxisome
|
|
Salmonella infection
|
|
Pertussis
|
|
Leishmaniasis
|
|
Chagas disease (American trypanosomiasis)
|
|
Toxoplasmosis
|
|
Amoebiasis
|
|
Tuberculosis
|
|
Pathways in cancer
|
|
Small cell lung cancer
|
|
NetPath Pathway
|
Wnt Signaling PathwayNetPath_4:EGFR1 Signaling PathwayNetPath_13:IL1 Signaling Pathway
|
|
IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Angiogenesis
|
|
Endothelin signaling pathway
|
|
Interleukin signaling pathway
|
|
PI3 kinase pathway
|
|
VEGF signaling pathwayP06959:CCKR signaling map ST
|
|
Pathway Interaction Database
|
Plasma membrane estrogen receptor signaling
|
|
Validated transcriptional targets of AP1 family members Fra1 and Fra2
|
|
Angiopoietin receptor Tie2-mediated signaling
|
|
Thromboxane A2 receptor signaling
|
|
SHP2 signaling
|
|
VEGFR1 specific signals
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
PAR1-mediated thrombin signaling eventsil12_2pathway:IL12-mediated signaling events
|
|
Alpha9 beta1 integrin signaling events
|
|
ATF-2 transcription factor network
|
|
IL23-mediated signaling events
|
|
Signaling mediated by p38-alpha and p38-beta
|
|
HIF-1-alpha transcription factor network
|
|
PathWhiz Pathway
|
Arginine and Proline Metabolism
|
|
Reactome
|
ROS production in response to bacteria
|
|
Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
|
|
eNOS activation
|
|
Nitric oxide stimulates guanylate cyclase
|
|
VEGFR2 mediated vascular permeabilityR-HSA-1222556:ROS production in response to bacteria
|
|
Nitric oxide stimulates guanylate cyclaseR-HSA-1222556:ROS production in response to bacteria
|
|
WikiPathways
|
ACE Inhibitor Pathway
|
|
EGF/EGFR Signaling Pathway
|
|
Myometrial Relaxation and Contraction Pathways
|
|
JAK/STAT
|
|
Corticotropin-releasing hormone
|
|
AGE/RAGE pathway
|
|
Endothelin Pathways
|
|
Leptin signaling pathway
|
|
Effects of Nitric Oxide
|
|
Metabolism of nitric oxide
|
|
AngiogenesisWP727:Monoamine Transport
|
|
Amyotrophic lateral sclerosis (ALS)
|
|
Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis
|
|
Spinal Cord Injury
|
|
Alzheimers Disease
|
|
Serotonin Transporter ActivityWP619:Type II interferon signaling (IFNG)
|
| References |
| REF 1 | Bioorg Med Chem. 2008 Dec 15;16(24):10205-9. Epub 2008 Oct 29.Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. |
|---|
